Table 2.
Patient characteristics of the studies included in the meta-analysis.
| Intervention (PRP) Group | Control (TrA) Group | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| First Author, Year of Publication | Number of Patients | Age, Mean (SD) |
Sex (Female % of Total) | Baseline SALT Score, Mean (SD) |
Post-Treatment SALT Score, Mean (SD) |
Numberof Patients | Age, Mean (SD) |
Sex (Female % of Total) | Baseline SALT Score, Mean (SD) |
Post-Treatment SALT Score, Mean (SD) |
| Albalat, 2019 [15] | 40 | 30.8 (7.5) | 15.0 | 1.7 (0.9) | 0.4 (0.7) | 40 | 36.3 (11.3) | 15.0 | 1.7 (0.8) | 0.5 (0.8) |
| Fawzy, 2020 [17] | 17 | 31.4 (10.6) | 23.5 | 5.6 (8.4) | 3.8 (8.4) | 14 | 34.2 (12.3) | 28.6 | 4.2 (4.4) | 1.4 (1.8) |
| Hegde, 2020 [18] | 25 | N/A | N/A | 7.2 (3.8) | 4.0 (5.3) | 25 | N/A | N/A | 8.8 (5.8) | 3.1 (5.1) |
| Kapoor, 2020 [19] | 20 | 25.4 (4.9) | 45.0 | 4.4 (2.5) | 3.2 (2.0) | 20 | 28.8 (8.6) | 65.0 | 9.0 (1.4) | 3.1 (0.8) |
SD: standard deviation; N/A: data not available; PRP: platelet-rich plasma; TrA: triamcinolone acetonide; SALT score: Severity of Alopecia Tool score.